Indication: Breast Cancer
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezol
Drug Study
Principal Investigator: Jeffrey Hargis, M.D.Norton Cancer Institute
Sponsor: National Surgical Adjuvant Breast and Bowel Projec
Learn more at ClinicalTrials.gov
Email for more information: Breast-NCIResearch@nortonhealthcare.org
